Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.54 |
| ▸ | FLT1 | P17948 | 3/20 | 0.54 |
| ▸ | FLT4 | P35916 | 3/20 | 0.54 |
| ▸ | BMP4 | P12644 | 3/20 | 0.48 |
| ▸ | MARK3 | P27448 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477974 | 0.89 | KDR (0.57) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL4466233 | 0.85 | KDR (0.56) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL4474545 | 0.83 | KDR (0.55) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL4479049 | 0.81 | KDR (0.59) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL4479183 | 0.77 | KDR (0.58) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL4477345 | 0.75 | KDR (0.62) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL13818131 | 0.74 | KDR (0.52) | KDRFLT1FLT4BMP4 | |
| SCHEMBL4469276 | 0.74 | KDR (0.57) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL4465890 | 0.72 | KDR (0.60) | KDRFLT1FLT4BMP4MARK3 | |
| SCHEMBL3319796 | 0.72 | KDR (0.57) | KDRFLT1FLT4BMP4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20060025426-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | claimed |
| WO-2004052315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550470-B2 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060025426-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| WO-2004052315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025426-A1 | Tyrosine kinase inhibitors | FLT1, FLT4, KDR | KDR 3/4885FLT1 1/4885FLT4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.